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Abstract
Background: There is currently much interest in encouraging individuals to increase physical
activity in order to reduce CVD risk. This study has been designed to determine if personalised
CVD risk appreciation can increase physical activity in adults at high risk of CVD.
Methods/Design: In a 2 × 2 factorial design participants are allocated at random to a personalised
10-year CVD risk estimate or numerical CVD risk factor values (systolic blood pressure, LDL
cholesterol and fasting glucose) and, simultaneously, to receive a brief lifestyle advice intervention
targeting physical activity, diet and smoking cessation or not. We aim to recruit 200 participants
from Oxfordshire primary care practices. Eligibility criteria include adults age 40–70 years,
estimated 10-year CVD risk ≥20%, ability to read and write English, no known CVD and no physical
disability or other condition reducing the ability to walk. Primary outcome is physical activity
measured by ActiGraph accelerometer with biochemical, anthropometrical and psychological
measures as additional outcomes. Primary analysis is between group physical activity differences at
one month powered to detect a difference of 30,000 total counts per day of physical activity
between the groups. Additional analyses will seek to further elucidate the relationship between the
provision of risk information, and intention to change behaviour and to determine the impact of
both interventions on clinical and anthropometrical measures including fasting and 2 hour plasma
glucose, fructosamine, serum cotinine, plasma vitamin C, body fat percentage and blood pressure.
Discussion: This is a pilot trial seeking to demonstrate in a real world setting, proof of principal
that provision of personalised risk information can contribute to behaviour changes aimed at
reducing CVD risk. This study will increase our understanding of the links between the provision
of risk information and behaviour change and if successful, could be used in clinical practice with
little or no modification.
Background
Assessment of physical activity is a key element of CVD
risk evaluation [1]. A lack of regular physical activity may
contribute to the early onset and progression of cardiovas-
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cular disease (CVD) in all individuals and almost any
increase in physical activity is likely to result in health
benefits. Physical activity has a wide variety of beneficial
effects on the course of atherosclerosis, resulting in a
20–25% reduction in overall mortality[2].
For individuals with type 2 diabetes CVD risk is an
immense problem as they have a 2–4 times greater CVD
risk compared with non-diabetic individuals, even after
adjustment for age, ethnicity, income, cholesterol level,
systolic blood pressure and smoking[3]. Importantly, it is
now recognised that increased risk of CVD is apparent
long before the diagnosis of type 2 diabetes is made [4-6].
Physical activity reduces CVD risk and its impact is great-
est in those at highest risk[7]. This is seen even when
adjusting for weight loss indicating that physical activity is
an independent risk factor for CVD and can provide some
protection in those at highest risk[7,8]. In a meta-analysis
of trials to promote physical activity among people with
type 2 diabetes a 0.6% reduction in HbA1c was seen[9].
Individuals at risk of developing type 2 diabetes also ben-
efit from physical activity as lifestyle interventions includ-
ing physical activity have been shown to prevent or delay
the onset of type 2 diabetes [10-12].
The beneficial effects of physical activity on CVD risk are
mediated through a lowering of blood pressure, increas-
ing HDL cholesterol, reducing body fat and reducing insu-
lin resistance[7]. To date trials evaluating behaviour
change interventions have been limited by a lack of use of
objective measures of physical activity favouring impre-
cise self-report methods[13].
The study, conducted in individuals at high estimated
CVD risk, aims to determine if the provision of individu-
alised information about future CVD risk can be used suc-
cessfully to change behaviour. Research from other fields
indicates that interventions including an individualised
risk estimate can have an impact on behaviour[14], partic-
ularly in those whose risk is higher than average for their
age and sex[15].
Brief lifestyle interventions have been shown to be effec-
tive in preventing and treating type 2 diabetes[16] and in
preventing the complications of diabetes including reduc-
ing CVD risk[17,18]. We expect to find that providing per-
sonalised CVD risk information or lifestyle advice to
individuals at increased risk of CVD can increase the
amount of physical activity they perform per day, com-
pared with risk factor information alone or no lifestyle
information. In turn, we expect also to see improvement
in the levels of the other CVD risk factors measured.
Methods/Design
Primary objective
To determine the efficacy of each intervention for increas-
ing physical activity at one month compared with CVD
risk factor values and to determine if brief lifestyle advice
versus no lifestyle advice can increase physical activity at
one month.
Secondary Objectives
To determine the efficacy of each intervention in modify-
ing the following CVD risk factors: smoking status, fruit
and vegetable intake, alcohol consumption, fasting and 2-
hour post-challenge plasma glucose, fructosamine, waist
circumference, weight, BMI, total cholesterol, HDL cho-
lesterol, LDL cholesterol and triglycerides, systolic and
diastolic blood pressure, estimated 10-year CVD risk, esti-
mated risk of diabetes and body fat percentage.
Tertiary Objectives
To determine the efficacy of each intervention on anxiety,
quality of life, self-regulation, worry about future risk of
heart attacks, intention to increase physical activity and
recall of risk information given.
Methods/design
Study Design
This is a pilot study to investigate the feasibility of a larger
scale randomised controlled trial and is a 2 × 2 factorial
design with 46 participants in each cell (Figure 1). This is
considered to be the most appropriate and efficient
method of answering the research question posed. Each
participant will receive an individualised cardiovascular
disease risk estimate or CVD risk factor values plus stand-
ardised brief lifestyle advice or not. The trial is being man-
aged by a UK Clinical Research Collaboration Clinical
Trials Unit, the Diabetes Trials Unit, University of Oxford,
UK. Ethical approval was granted by the Milton Keynes
Local Research Ethics Committee in September 2007.
Physical activity, clinical and psychological information
will be collected before randomisation and one month
after delivery of the intervention. A personalised CVD risk
estimate and lifestyle advice will be provided to all partic-
ipants at the end of 4 weeks making it a waiting-list con-
trol design. The inclusion of a control group receiving
neither a risk estimate or lifestyle advice but undergoing
baseline and follow up measurement will control for
Hawthorne effects[19].
Practices and participants
GP practices from Oxfordshire have been recruited. Partic-
ipant eligibility criteria are adults aged 40–70 years, esti-
mated 10-year CVD risk ≥20%, not known to have
cardiovascular disease as defined by a history of myocar-
dial infarction, other incident ischaemic heart disease,Cardiovascular Diabetology 2008, 7:21 http://www.cardiab.com/content/7/1/21
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stroke, coronary or peripheral revascularisation, or tran-
sient ischaemic attack, not known to have a physical disa-
bility or other condition reducing the ability to walk, and
able to read and write English.
Screening eligibility
Participating practices allowed a member of the research
team who holds an honorary contract with the Primary
Care Trust, to identify eligible participants from practice
databases. Once identified, lists of potentially eligible par-
ticipants were constructed and general practitioners asked
to review the list for suitability prior to sending out invi-
tations to take part in the study. Participant invitation let-
ters were sent out randomly in batches of 60 (figure 1).
Telephone contact
Once a participant has expressed interest in taking part in
the study by returning a reply slip in a prepaid envelope
or by emailing or telephoning the research team a
researcher obtains verbal consent and arranges a date and
time for visit 1. ActiGraph accelerometers (model GT1M,
Manufacturing Technology, Fort Walton Beach, FL) are
then mailed to recruited participants approximately one
week prior to visit 1 in order to reduce the number of visits
and to reduce the potential effect of measurement on
baseline physical activity. Simple instructions on how to
use the device are provided and participants are asked to
wear the accelerometer for seven days in total over a mix-
ture of week and weekend days. Accelerometers are worn
Figure 1
 
 
 
  UKPDS risk estimate 
 Yes  No 
 
Yes  46 46 92  Lifestyle 
advice 
No  46 46 92 
  92 92  184 
x  Practice visited by researcher and records searched to identify 
eligible participants 
x  List of eligible participants reviewed by general practitioner to 
ensure appropriate to be approached to take part in research study 
x  Participants invited to take part 
x  Participant returns reply slip expressing interest in taking part 
x  Research nurse telephones participant to obtain verbal consent to 
send participant an accelerometer and to arrange a date and time for 
visit 1 
x  Participant attends visit one for baseline assessment 
x  Randomisation occurs simultaneously to risk estimate or no risk 
estimate and lifestyle advice or no lifestyle advice
x  1 month follow-up 
x  Follow-up for all measures 
x  Delivery of interventions to participants not randomised to receive 
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on an elastic belt around the waist and are removed for
sleep, bathing, showering and swimming.
Baseline assessment
Baseline clinical assessment is conducted by a clinical
researcher and research nurses prior to randomisation in
a clinical research unit. Written informed consent is col-
lected at this visit. Medical history, demographic details,
age at leaving school and electoral ward are collected. A 75
mg anhydrous oral glucose tolerance test (0 and 120
minute glucose sampling) is conducted and fasting blood
samples taken for total, LDL and HDL cholesterol, triglyc-
erides, HbA1c, serum cotinine, plasma vitamin C and
fructosamine assessment. Anthropometric measurements
are taken (resting blood pressure, height, weight, waist cir-
cumference, body fat percentage). Smoking status, current
medication and self-reported alcohol intake is recorded.
An ECG is performed. A booklet of questionnaires com-
prising the short-form Spielberger anxiety inventory[20],
EQ5D questionnaire[21], Illness perception question-
naire, adapted Lerman cancer worry scale[22], psycholog-
ical impact questionnaire, Recent Physical Activity
Questionnaire (RPAQ) and A Fear-Avoidance Beliefs
Questionnaire (FAB) is completed by each participant.
Once these data have been collected the participant is ran-
domised and any interventions delivered at this study
visit.
Outcome assessment
Follow-up at four weeks occurs for all measures including
oral glucose tolerance test, blood samples, anthropomet-
ric measurements, smoking status, current medication,
alcohol intake and questionnaires with the addition of a
recall of risk information questionnaire. Physical activity
is again measured by accelerometer for seven days in the
week before the second study visit.
Randomisation
Computer randomisation is used to allocate participants
to each of the interventions in blocks of four. No minimi-
sation is used. Research nurses who input data are blind
to intervention allocation. One research fellow will
remain unblinded in order to deliver the interventions.
All research nurses working on the study have undergone
training in the protocol and electronic data capture system
prior to the study commencing.
The interventions
Participants randomised to receive a risk estimate will
have their 10-year CVD and fatal CVD risk estimated using
a modified version of the UKPDS Risk Engine[23]. This
has an interface designed specifically for use in the study
with the aim of achieving maximum comprehension by
participants. Participants will be shown their current risk
and also their 'achievable risk' i.e. the risk estimate they
could achieve if they were to meet current targets[24] for
systolic blood pressure, LDL cholesterol, HbA1c and
smoking cessation (if applicable). Participants will be
given a UKPDS Risk Engine print out showing their cur-
rent and achievable risk. Those participants not ran-
domised to a 10-year CVD risk estimate will be informed
of their LDL cholesterol, fasting plasma glucose and blood
pressure values and informed if they are elevated accord-
ing to current guidelines[24].
The lifestyle intervention used is based on self-regulation
theory [25] and involves goal setting and steering behav-
iour towards goal achievement[26]. It also acknowledges
the other priorities in participant's lives including family
and financial constraints and encourages them to set goals
around these commitments and states that any change in
a positive direction is beneficial. This theoretical approach
has been used in other studies attempting to motivate
behaviour change in a similar population [27]. Partici-
pants randomised to receive the lifestyle advice interven-
tion will receive a computer presentation. This
presentation will focus on encouraging participants to
increase their physical activity and fruit and vegetable
intake and to decrease their alcohol intake and stop smok-
ing if necessary. The physical activity goal will be 30 min-
utes of brisk walking per day in line with current
guidelines[28]. Instant feedback of physical activity for
example by using pedometers, is not provided as part of
the study. The fruit and vegetable goal will be five portions
per day in line with current UK government recommenda-
tions [29]. A reduction in alcohol consumption will only
be advised if current intake is above UK government rec-
ommendations (not more than 3–4 units per day for men
and 2–3 units per day for women)[30].
Trial Management
The day-to-day management of the study will be under-
taken by a clinical research fellow. Support will be pro-
vided by the co-investigators who will meet on an at least
quarterly basis to discuss any matters that arise will the
trial. The intervention is low risk and as such there will be
no data monitoring committee. As this is not a clinical
trial of an investigational medicinal product (CTIMP),
there is no requirement for Medicines and Healthcare
products Regulatory Agency (MHRA) approval or trial reg-
istration.
Quality assurance
The Study will be conducted by trained personnel follow-
ing departmental Standard Operating Procedures with
Quality Control. Standardised delivery of the interven-
tions will be assured by all interventions being delivered
by one clinical research fellow using a computerised inter-
vention. Source data verification will be performed byCardiovascular Diabetology 2008, 7:21 http://www.cardiab.com/content/7/1/21
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monitors from the University of Oxford Clinical Trials
and Research Governance department.
Sample size and rate of recruitment
The study has 80% power at the 5% level of significance
to detect a difference of 30,000 total accelerometer counts
per day of physical activity between the groups with a
sample size of 46 per cell, assuming the estimated total
counts per day is mean (SD) 275,400 (101,600) min-
utes[31]. This equates to 92 participants per arm of the
study. We will randomise a total of 200 subjects to allow
for a small drop-out rate. We expect retention of study par-
ticipants to be high because of the short duration and
non-invasiveness of the study. Recruitment is anticipated
to continue for one year.
Statistical analysis
Only data for participants who record at least 500 min/
day of activity for at least 4 days during each 7 day period
will be analysed. Data will be presented in terms of total
body movement (counts·day-1), which is an indicator of
the total volume of physical activity, and time
(minutes·day-1) spent at different activity intensity cate-
gories averaged per day over the measurement period.
Intensity thresholds for sedentary, light, moderate, vigor-
ous and very vigorous intensity physical activity will be
defined according to Freedson et al and Ekelund et
al[32,33]. We will also determine the average number of
5- and 10-min bouts of sustained physical activity at mod-
erate or greater intensity allowing 1 min to drop below the
threshold for moderate activity in each 5-min bout. We
will calculate the proportion of participants in each group
accumulating 30 min or more per day of moderate or
greater intensity physical activity, the current UK recom-
mendation for physical activity[28]. Data reduction,
cleaning, and analyses of accelerometer data will be per-
formed using appropriate software (MAHUffe; see http://
www.mrc-epid.cam.ac.uk). Generalized linear model
(Poisson distribution or Negative Binomial distribution)
as appropriate will be used and estimates of Rate Ratios
along with 95% confidence interval will be presented.
Demographic, clinical and biochemical study variables
will be summarized using number (percentage) and
measures of location and dispersion as appropriate. The
change in the study parameters from baseline to one
month will be analysed and inference drawn using appro-
priate statistical methods, keeping in mind the nature of
distributions of the study variables. Analysis will be by
intention to treat (ITT).
To analyse the highly skewed EQ-5D scores, appropriate
non-parametric technique will be used. Other question-
naire data will be analysed using appropriate non-para-
metric tests to compare average scores as well as
distribution of scores in each group. Should a question-
naire generate only a finite number of scores, the data will
then be considered polytomous and suitable statistical
techniques will be used to analyse any such data.
Any missing biochemical data will be imputed using the
Last Observation Carried Forward technique. Any missing
accelerometer data however, will not be imputed for.
Publication of results
It is anticipated that the results of the study will be pub-
lished towards the end of 2009.
Discussion
The aim of this study is to evaluate whether provision of
personalised 10-year CVD risk estimates can increase
intention to change behaviour and increase physical activ-
ity in individuals at high risk of CVD. The simultaneous
randomisation to a risk estimate or not and to a lifestyle
advice intervention or not will allow us to determine
whether 10-year CVD risk information can increase inten-
tion to change behaviour and also if a brief lifestyle advice
intervention can increase intention to change behaviour.
The evidence that increased physical activity can reduce
CVD is well established but our study represents a novel
approach at trying to increase physical activity in a high
risk group.
The outcome measures used have been chosen to provide
objective measures of behaviour without undue incon-
venience to participants. Accelerometers have been cho-
sen as a measure of physical activity because they allow
measurement of free living physical activity, avoid the
need for whole-room calorimetry and are more accurate
than the completion of physical activity questionnaires.
100,000 accelerometer counts are approximately equiva-
lent to 30 minutes of brisk walking in a person of average
size. In the MRC PROACTIVE trial, a behavioural inter-
vention to promote physical activity among the 20–50
year old offspring of people with type 2 diabetes, the
cohort exhibited a 10,000 increase in total counts per day
between baseline (mean counts per day 264,000) and fol-
low-up at one year (mean counts per day 274,000)[31].
Plasma vitamin C provides a robust measure of fruit and
vegetable intake and has been shown to be inversely
related to mortality from cardiovascular disease and
ischaemic heart disease in men and women[34]. Serum
cotinine is a reliable objective indicator of the quantity of
tobacco smoked [35].
The Illness Perception Questionnaire has been included
to provide insight into the influence of self-regulation on
the decision to adhere to medical advice [36].Cardiovascular Diabetology 2008, 7:21 http://www.cardiab.com/content/7/1/21
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The study also includes measurements of potential medi-
ators and moderators. Personality traits in particular opti-
mism and pessimism (future orientation), are known to
influence response to health information[37] this is meas-
ured by questionnaire[38] in order to examine its effect
on the results of the study. Deprivation and a feeling of
being unsafe in a community have been shown to be asso-
ciated with lower rates of physical activity[29]. We collect
age at leaving school and electoral ward as surrogate
measures of deprivation. In order to investigate the
impact of considering oneself already active on the results
of the study we are using a recent physical activity ques-
tionnaire[39]. An adapted Lerman Cancer Worry Scale is
being used to assess the impact of CVD risk information
on worry about diabetes[22] although work in the field of
pre-natal genetic screening suggests that numerical risk
information can be successfully communicated to indi-
viduals and increase awareness of risk without raising anx-
iety[40].
Studies to investigate the use of personalised risk informa-
tion are needed across a wide range of clinical topics to
explore the impact of individualised risk estimates on
knowledge, attitude, behaviour and patient understand-
ing[41] with the aim of demonstrating a link between
informed decision making and behaviour change[42]. We
hope to demonstrate proof of principal that personalised
risk information and brief theory-based advice can pro-
vide motivation to initiate behaviour change and to exam-
ine the intermediate measures that link changing beliefs
to subsequent behaviour change. We have included a
robust measure of physical activity and our intervention
focuses on increasing activity as part of day to day life, fac-
tors that have limited the interpretation and applicability
of other studies[13].
This project, if successful, has a high probability of provid-
ing generalisable results. Personalised risk scores can read-
ily be assessed in many clinical situations and the
intervention tested could be used in almost all individuals
without modification.
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